Medical Association A. Issue brief: Reports of increases in opioid-related overdose and other concerns during COVID pandemic [Internet]. 2020. https://chicago.suntimes.com/2020/5/13/21257820/dupage-opioid-overdose-death. Accessed 1 June 2020.

The Ontario Drug Policy Research Network, The Office of the Chief Coroner for Ontario/Ontario Forensic Pathology Service, Public Health Ontario, Centre on Drug Policy Evaluation. Preliminary Patterns in Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic. 2020;(November):1–24. https://www.publichealthontario.ca/-/media/documents/o/2020/opioid-mortality-covid-surveillance-report.pdf?la=en. Accessed 14 Feb 2021.

British Columbia Centre for Disease Control. Illegal Drug Overdose Events [Internet]. Overdose Response Reports. 2020. p. 1. http://www.bccdc.ca/health-professionals/data-reports/illegal-drug-overdose-events. Accessed 14 Feb 2021.

Manthey J, Kilian C, Dresden TU, Carr S, Bloomeld K, Braddick F, et al. Use of alcohol, tobacco, cannabis, and other substances during the first wave of the SARS-CoV-2 pandemic in Europe: a survey on 36,000 European Substance Users. 2021 Jan 22. https://doi.org/10.21203/rs.3.rs-150691/v1. Accessed 14 Feb 2021.

Cowan E, Khan MR, Shastry S, Edelman EJ. Conceptualizing the effects of the COVID-19 pandemic on people with opioid use disorder: an application of the social ecological model [Internet]. Vol. 16, Addiction Science and Clinical Practice. BioMed Central Ltd; 2021. p. 4. https://ascpjournal.biomedcentral.com/articles/https://doi.org/10.1186/s13722-020-00210-w. Accessed 3 Feb 2021.

Haley DF, Saitz R. The opioid epidemic during the COVID-19 pandemic. JAMA [Internet]. 2020. https://jamanetwork.com/journals/jama/fullarticle/2770985. Accessed 23 Sept 2020.

Wakeman SE, Green TC, Rich J. An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nat Med. 2020;1–2. http://www.nature.com/articles/s41591-020-0898-0. Accessed 19 May 2020.

Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med [Internet]. 2020. http://www.ncbi.nlm.nih.gov/pubmed/32240283. Accessed 8 Apr 2020.

Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry [Internet]. 2020;1–10. http://www.nature.com/articles/s41380-020-00880-7. Accessed 18 Sept 2020.

Allen B, El Shahawy O, Rogers E, Hochman S, Khan M, Krawczyk N. Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020. J Public Health (Bangkok) [Internet]. 2020. https://pubmed.ncbi.nlm.nih.gov/33367823/. Accessed 29 Dec 2020.

Krawczyk N, Mojtabai R, Stuart E, Fingerhood M, Agus D, Lyons BC, et al. Opioid agonist treatment and fatal overdose risk in a statewide population receiving opioid use disorder services. Addiction. 2020.

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.

Article  Google Scholar 

Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.

Article  Google Scholar 

McDonald R, Campbell ND, Strang J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids—conception and maturation. Vol. 178, Drug and Alcohol Dependence. Elsevier Ireland Ltd; 2017. p. 176–87.

Saloner B, McGinty EE, Beletsky L, Bluthenthal R, Beyrer C, Botticelli M, et al. A public health strategy for the opioid crisis. Public Health Rep. 2018;133(1_suppl):24S-34S. https://doi.org/10.1177/0033354918793627.

Article  PubMed  PubMed Central  Google Scholar 

Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019;16(11):e1002969. https://doi.org/10.1371/journal.pmed.1002969.

Article  PubMed  PubMed Central  Google Scholar 

Krawczyk N, Fingerhood MI, Agus D. Lessons from COVID 19: are we finally ready to make opioid treatment accessible? J Subst Abuse Treat. 2020. https://doi.org/10.1016/j.jsat.2020.108074.

Article  PubMed  PubMed Central  Google Scholar 

Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020. https://doi.org/10.1186/s12954-020-00370-7.

Article  PubMed  PubMed Central  Google Scholar 

Krawczyk N, Bunting AM, Frank D, Arshonsky J, Gu Y, Friedman SR, et al. “How will I get my next week’s script?” Reactions of Reddit opioid forum users to changes in treatment access in the early months of the coronavirus pandemic. Int J Drug Policy. 2021;92:103140.

Article  Google Scholar 

Substance Abuse and Mental Health Services Administration. FAQs: provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19. 2020;5–7. https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf. Accessed 9 Sept 2020.

Ahamad K, Bach P, Brar R, Chow N, Coll N, Compton M, et al. Risk mitigation in the context of dual public health emergencies: interim clinical guidance [Internet]. 2020. http://bcyadws.ca/sites/default/files/2020-04/Risk-Mitigation-in-the-Context-of-Dual-Public-Health-Emergencies.pdf. Accessed 14 Sept 2021.

Nosyk B, Slaunwhite A, Urbanoski K, Hongdilokkul N, Palis H, Lock K, et al. Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol. BMJ Open [Internet]. 2021;11(6):e048353. https://bmjopen.bmj.com/content/11/6/e048353. Accessed 14 Sept 2021.

Victoria State Government Health and Human Services. Coronavirus (COVID-19) Response Pharmacotherapy services: information for prescribers and dispensers [Internet]. 2020. https://www2.health.vic.gov.au/public-health/drugs-and. Accessed 14 Feb 2021.

Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467. https://doi.org/10.7326/M18-0850.

Article  PubMed  Google Scholar 

Chen Q, Allot A, Lu Z. LitCovid: an open database of COVID-19 literature. Nucleic Acids Res [Internet]. 2021;49(D1):D1534–40. https://academic.oup.com/nar/article-abstract/49/D1/D1534/5964074. Accessed 30 Mar 2021.

Larsen KL, Linares BM. LitCovid: a database of coronavirus research. Med Ref Serv Q. 2021;40(1):103–9.

Article  Google Scholar 

Kellermeyer L, Harnke B, Knight S. Covidence and rayyan. J Med Libr Assoc. 2018;106(4):580.

Article  Google Scholar 

Popay J, Arai L, Rodgers M, Britten N. Guidance on the conduct of narrative synthesis in systematic reviews: a product from the ESRC Methods Programme Communities in Control-Big Local Evaluation View project VOICES (ViOlence: Impact on Children Evidence Synthesis) View project. 2006. https://www.researchgate.net/publication/233866356. Accessed 9 Apr 2021.

Crowley D, Delargy I. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report. Harm Reduct J. 2020;17(1):49. https://doi.org/10.1186/s12954-020-00394-z.

Article  PubMed  PubMed Central  Google Scholar 

Samuels EA, Clark SA, Wunsch C, Jordison Keeler LA, Reddy N, Vanjani R, et al. Innovation during COVID-19: improving addiction treatment access. J Addict Med. 2020;14(4):e8-9.

Article  CAS  Google Scholar 

Singh LK, Tikka SK. Nondisrupted, safety ensured, opioid substitution clinic in a COVID-19 designated hospital of a resource-limited state in India. Asia Pacific Psychiatry. 2020. https://doi.org/10.1111/appy.12428.

Article  PubMed  Google Scholar 

Vecchio S, Ramella R, Drago A, Carraro D, Littlewood R, Somaini L. COVID19 pandemic and people with opioid use disorder: innovation to reduce risk. Psychiatry Res. 2020;289:113047.

Article  CAS  Google Scholar 

Quiñones D, Melin K, Roman L, Rodriguez F, Alvarado J, Rodriguez-Diaz CE. Treating opioid use disorder in puerto rico during the COVID-19 pandemic: providers’ leadership efforts in unprecedented times. J Addict Med [Internet]. 2020. https://europepmc.org/article/med/33229933. Accessed 30 Mar 2021.

Castillo M, Conte B, Hinkes S, Mathew M, Na CJ, Norindr A, et al. Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):88. https://doi.org/10.1186/s12954-020-00438-4.

Article  PubMed  PubMed Central  Google Scholar 

Tringale R, Subica AM. COVID-19 innovations in medication for addiction treatment at a Skid Row syringe exchange. J Subst Abuse Treat. 2021;121:108181. https://doi.org/10.1016/j.jsat.2020.108181.

Article  PubMed  Google Scholar 

Nordeck CD, Buresh M, Krawczyk N, Fingerhood M, Agus D. Adapting a low-threshold buprenorphine program for vulnerable populations during the COVID-19 pandemic. J Addict Med [Internet]. 2020. https://europepmc.org/article/med/33177436. Accessed 30 Mar 2021.

Harris M, Johnson S, Mackin S, Saitz R, Walley AY, Taylor JL. Low barrier tele-buprenorphine in the time of COVID-19: a case report. J Addict Med. 2020;14(4):e136–8.

Article  CAS  Google Scholar 

Duncan A, Sanders N, Schiff M, Winkelman TNA. Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic. J Subst Abuse Treat. 2021;121:108161.

Article  Google Scholar 

Komaromy M, Tomanovich M, Taylor JL, Ruiz-Mercado G, Kimmel SD, Bagley SM, et al. Adaptation of a system of treatment for substance use disorders during the COVID-19 pandemic. J Addict Med [Internet]. 2020. https://europepmc.org/article/med/33298750. Accessed 30 Mar 2021.

Hughto JMW, Peterson L, Perry NS, Donoyan A, Mimiaga MJ, Nelson KM, et al. The provision of counseling to patients receiving medications for opioid use disorder: telehealth innovations and challenges in the age of COVID-19. J Subst Abuse Treat. 2021;120:108163.

Article  Google Scholar 

McKiever ME, Cleary EM, Schmauder T, Talley A, Hinely KA, Costantine MM, et al. Unintended consequences of the transition to telehealth for pregnancies complicated by opioid use disorder during the coronavirus disease 2019 pandemic. Am J Obstetr Gynecol. 2020;223:770–2.

Article  Google Scholar 

Courser MW, Raffle H. With crisis comes opportunity: unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic. J Subst Abuse Treat. 2021;122:108220.

Article  Google Scholar 

Peavy KM, Darnton J, Grekin P, Russo M, Green CJB, Merrill JO, et al. Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program. AIDS Behav. 2020;24:2469–72.

Article  Google Scholar 

MacKinnon L, Socías ME, Bardwell G. COVID-19 and overdose prevention: challenges and opportunities for clinical practice in housing settings. J Subst Abuse Treat. 2020;119:108153.

Article  Google Scholar 

Basu D, Ghosh A, Subodh B, Mattoo S. Opioid substitution therapy with buprenorphine-naloxone during COVID-19 outbreak in India: sharing our experience and interim standard operating procedure. Indian J Psychiatry. 2020;62(3):322.

Article  Google Scholar 

Trujols J, Larrabeiti A, Sànchez O, Madrid M, De Andrés S, Duran-Sindreu S. Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: should this practice be incorporated into routine clinical care? J Subst Abuse Treat. 2020;119:108154.

Article  Google Scholar 

Hazan J, Congdon L, Sathanandan S, Grewal P. An analysis of initial service transformation in response to the COVID-19 pandemic in two inner-city substance misuse services. J Subst Use. 2020. https://doi.org/10.1080/14659891.2020.1820089.

Article  Google Scholar 

Ghosh A, Singh S, Dutta A. Opioid agonist treatment during SARS-CoV2 & extended lockdown: adaptations & challenges in the Indian context. Asian J Psychiatry. 2020;53:102377.

Article  Google Scholar 

Straub A, Pastor A, Lloyd-Jones M, O’Neill H, Bonomo Y. The development and implementation of a rapid-access long-acting injectable buprenorphine clinic in metropolitan Melbourne during the COVID-19 pandemic. Drug Alcohol Rev. 2020. https://doi.org/10.1111/dar.13161.

Article  PubMed  Google Scholar 

Wenzel K, Fishman M. Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: an adaptation to the COVID-19 emergency. J Subst Abuse Treat. 2021;120:108149.

Article  Google Scholar 

Roberts J, White B, Attalla D, Ward S, Dunlop AJ. Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia. Addiction. 2021;116:426–7.

Article  Google Scholar 

Warrington JS, Brett A, Foster H, Brandon J, Francis-Fath S, Joseph M, et al. Driving access to care: use of mobile units for urine specimen collection during the coronavirus disease-19 (COVID-19) pandemic. Acad Pathol. 2020. https://doi.org/10.1177/2374289520953557.

Article  PubMed  PubMed Central  Google Scholar 

Harris MTH, Peterkin A, Bach P, Englander H, Lapidus E, Rolley T, et al. Adapting inpatient addiction medicine consult services during the COVID-19 pandemic. Addict Sci Clin Pract. 2021. https://doi.org/10.1186/s13722-021-00221-1.

Article  PubMed  PubMed Central  Google Scholar 

Marcus TS, Heese J, Scheibe A, Shelly S, Lalla SX, Hugo JF. Harm reduction in an emergency response to homelessness during South Africa’s COVID-19 lockdown. Harm Reduct J. 2020;17(1):60. https://doi.org/10.1186/s12954-020-00404-0.

Article  PubMed  PubMed Central  Google Scholar 

Joudrey PJ, Edelman EJ, Wang EA. Drive times to opioid treatment programs in urban and rural counties in 5 US States [Internet]. Vol. 322, JAMA Journal of the American Medical Association. American Medical Association; 2019, p. 1310–2. https://jamanetwork.com/journals/jama/fullarticle/2752051. Accessed 2 Oct 2019.

Reisinger HS, Schwartz RP, Mitchell SG, Peterson JA, Kelly SM, O’Grady KE, et al. Premature discharge from methadone treatment: patient perspectives. J Psychoactive Drugs. 2009;41(3):285–96. https://doi.org/10.1080/02791072.2009.10400539.

Article  PubMed  PubMed Central  Google Scholar 

Bourgois P. Disciplining addictions: the bio-politics of methadone and heroin in the United States. Cult Med Psychiatry. 2000;24(2):165–95.

Article  CAS  Google Scholar 

Gryczynski J, Mitchell SG, Jaffe JH, O’Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients’ reasons for cessation of care. J Subst Abuse Treat. 2014;46(3):356–61.

Article